What's a SNP between friends: the influence of single nucleotide polymorphisms on virulence and phenotypes of *Clostridium difficile* strain 630 and derivatives

Running Title: What's a SNP between Friends?

Mark M Collery [a,1,†], Sarah A Kuehne[a,b,2,†], Shonna M McBride[c], Michelle L Kelly[a], Marc Monot[d], Alan Cockayne[a], Bruno Dupuy[d], and Nigel P Minton[a,b,*]

[a] Clostridia Research Group, BBSRC/EPSRC Synthetic Biology Research Centre (SBRC), School of Life Sciences, University of Nottingham, Nottingham, UK; [b]NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK; [c] Department of Microbiology and Immunology, Emory Antibiotic Resistance Center, Emory University, Atlanta, USA, and; [d] Laboratoire Pathogenèse des Bactéries Anaérobies, Institut Pasteur, Paris, France.

***Corresponding to:** Nigel P Minton; Email: nigel.minton@nottingham.ac.uk

Current address: [1]Micropathology Ltd., University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry, UK and [2] current address: Dr Sarah A. Kuehne, School of Dentistry, Institute of Clinical Sciences, College of Medical & Dental Sciences, The University of Birmingham, Birmingham, UK.

[†] These authors contributed equally to the work.

Keywords: single nucleotide polymorphism; sporulation; motility; toxin expression; mutation; ClosTron; virulence

Abstract

Clostridium difficile is a major cause of antibiotic induced diarrhoea worldwide, responsible for significant annual mortalities and represents a considerable economic burden on healthcare systems. The two main *C. difficile* virulence factors are toxins A and B. Isogenic toxin B mutants of two independently isolated erythromycin-sensitive derivatives (630E and 630Δ*erm*) of strain 630 were previously shown to exhibit substantively different phenotypes. Compared to 630, strain 630E and its progeny grow slower, achieve lower final cell densities, exhibit a reduced capacity for spore-formation, produce lower levels of toxin and are less virulent in the hamster infection model. By the same measures, strain 630Δ*erm* and its derivatives more closely mirror the behaviour of 630. Genome sequencing revealed that 630Δ*erm* had acquired seven unique Single Nucleotide Polymorphisms (SNPs) compared to 630 and 630E, while 630E had nine SNPs and a DNA inversion not found in the other two strains. The relatively large number of mutations meant that the identification of those responsible for the altered properties of 630E was not possible, despite the restoration of three mutations to wildtype by allelic exchange and comparative RNAseq analysis of all three strains. The latter analysis revealed large differences in gene expression between the three strains, explaining in part why no single SNP could restore the phenotypic differences. Our findings suggest that strain 630Δ*erm* should be favoured over 630E as a surrogate for 630 in genetic-based studies. They also underline the importance of effective strain curation and the need to genome re-sequence master seed banks wherever possible.

Introduction

Clostridium difficile is a Gram-positive, anaerobic spore-forming bacterium capable of causing a range of diseases from mild diarrhoea to potentially fatal toxic pseudomembranous colitis. The toxigenic effects of *C. difficile* are caused by the activities of two large, glucosylating toxins. The two toxins are 308kDa (toxin A) and 270kDa (toxin B) in size [1-3] and are encoded by the chromosomally located genes *tcdA* and *tcdB*, respectively. Both are cytopathic to cultured cells due to disruption of the cytoskeleton, although TcdB is thought to be up to 1000-times more potent.[1] Historically, toxin A was regarded as the main causative agent of the symptoms of *C. difficile* infection (CDI). Pivotal data was provided by Lyerly et al.[4] who were only able to detect disease when hamsters were subject to intragastric challenge with purified TcdA alone and not with TcdB. The latter could, however, cause disease symptoms if prior damage to the mucosa had been inflicted by co-administration of sub-lethal concentrations of toxin A. Furthermore, co-administration of both toxins led to more severe disease symptoms. To accommodate these data, it was generally accepted that both toxins acted in concert to bring about disease symptoms, with toxin A leading to the initial damage to the colon allowing the subsequent access of the more potent toxin B.

During the 1990's *C. difficile* strains were isolated from symptomatic patients that only produced toxin B (A-B+)[5, 6]. These findings suggested that toxin B, at least in certain strains, is capable of causing disease without the help of toxin A. It has been reported since that toxin B, in A-B+ strains, is modified and seems to be an evolutionary hybrid of *C. difficile* toxin B and *Clostridium sordellii* lethal toxin.[7]

With the development of genetic systems, assumptions of the relative importance of the two toxins could be tested through the creation, and *in vivo* assay, of isogenic mutants in which production of either toxin had been ablated. Initial findings made by Lyras et al.[8] appeared to turn the perceived view on its head, through the demonstration that a *tcdA* mutant producing TcdB alone (A-B+) was capable of causing disease in the hamster model while a *tcdB* mutant producing only TcdA (A+B-) did not. These data were, however, almost immediately questioned by a second study conducted in the Minton laboratory [9] showing that both *tcdA* and *tcdB C. difficile* mutants, and therefore TcdA and TcdB alone, were independently capable of causing disease. Interestingly, a strain has recently[10] beren isolated from a clinical case of CDI, that only produces TcdA (A+B-)

The possible reasons for the observed difference in outcomes of the two studies have been discussed previously. [11] Both studies agree on the virulence potential of toxin B, but uncertainties remain about the different outcomes concerning the effects of toxin A. In the work presented here, we have hence focused on comparisons of the parental strains and the strains only producing toxin A (A+B-). In essence, both sets of mutants were generated by insertional inactivation of the toxin genes of the *C. difficile* strain 630 [12] and, once created, were tested in the hamster infection model. However, in order to implement the available gene tools in strain 630 (at the time the only strain for which a genome sequence was available), it was necessary to first isolate a variant that had become sensitive to erythromycin, thereby allowing the use of an *ermB* gene as a selective, genetic marker. Both studies used such an erythromycin-sensitive derivative of strain 630, but they were independently isolated. In our study (Minton group), [9] we used the strain 630Δ*erm,* isolated in the Mullany laboratory (UCL, London, UK) after 30 repeated subcultures of strain 630 in

92 non-selective media. [13] In parallel, the Rood laboratory (Monash, Australia) independently
93 isolated the erythromycin sensitive strain JIR8094 (also referred to as 630E), [14] through an
94 undisclosed number of subcultures of strain 630 in non-selective media. Both strains are
95 reported to possess the same specific deletion of *ermB*. [13, 14]

96 We have previously hypothesised [11] that the different outcomes of the two studies [8, 9]
97 are a direct consequence of the use of the two, independently isolated erythromycin-
98 sensitive strains, 630Δ*erm* and 630E. We suggested that during repeated subculture,
99 ancillary mutations arose which impacted on the virulence potential of one or other of the
100 two strains in the presence of different toxin gene alleles. In the current piece of work, we
101 have set out to test this hypothesis. We have undertaken side-by-side comparisons of
102 630Δ*erm* and 630E, and the A+B- mutant derivatives, in a variety of assays to establish
103 phenotypic differences. In parallel, we have determined the genome sequences of the
104 various strains used in the two studies. [8, 9] Then, we have used our newly developed allelic
105 exchange methodologies [15] to correct a number of SNPs in strain 630E back to wild-type and
106 assessed the consequences. Furthermore we have performed RNAseq experiments
107 comparing the transcriptome of 630, 630Δ*erm* and 630E at three different time points. The
108 RNA data were related to the whole genome data to draw our final conclusions.

109

110 ## Results

111 **Generation of a ClosTron insertion in *tcdB* of 630E**

112 Although considered unlikely, the possibility existed that mutants made by the insertion
113 of a plasmid element carrying *ermB* [14] might behave differently to an equivalent mutant
114 made by the insertion of a group II intron incorporating *ermB.* [16] Our initial step was,

115 therefore, to create a *tcdB* mutant of strain 630E using ClosTron technology. Accordingly,
116 the ClosTron plasmid pMTL007C-E2::Cdi-tcdB-1511a that had previously been used to
117 generate strain 630Δ*erm* A+B- [9] was used to create an equivalent mutant in strain 630E as
118 described. [9] The resulting mutant, 630E A+B-CT, was verified by PCR, Sanger sequencing and
119 shown by Southern blot to carry a single group II intron insertion (**Fig. S1A**). Parental strains,
120 original A+B- mutants and the newly obtained mutant were tested for production of toxin A
121 in a Western blot (**Fig. S1B**). As expected all strains produced toxin A.
122
123 **Phenotypic characterisation of strains**
124 In order to establish whether all strains were phenotypically identical a range of assays
125 were performed, comparing growth, motility and spore properties. An analysis of growth
126 rates using the procedure described in Materials and Methods showed that strain 630Δ*erm*
127 and derivatives grew to the highest optical density, closely followed by strain 630 and 630E,
128 and derivatives thereof (**Fig. 1A and 1B**). The data clearly demonstrated that strain 630Δ*erm*
129 and its 630Δ*erm* A+B- derivative had relatively higher growth rates and achieved higher
130 optical densities ($p < 0.0001$, unpaired t-test at 24 h) than strain 630E and its derivatives,
131 with strain 630E A+B-CT growing the least (**Fig. 1B**). It was also apparent, shown by plate
132 motility assay (**Fig. 2**), that strains 630 and 630Δ*erm* were motile, while 630E was not. Only
133 630 and 630Δ*erm*, but not 630E, form pseudopod-like structures, which are characteristic
134 for swarming motility in bacteria.
135 Following the protocols of Burns et al, [17] comparative differences in the numbers of
136 colony forming units (CFUs) obtained following heat shock were assessed between the
137 strains, as a crude estimate of spore formation. [18] On this basis, strains 630Δ*erm* and

630Δ*erm* A+B- produced a greater numbers of spores than 630E and its derivatives, which failed to produce any spores until 72 h. The total number of CFU/mL at this time point was 10^3 times fewer than that obtained with 630Δ*erm* or 630Δ*erm* A+B- (**Fig. 3A**). Interestingly parental strain 630 produced very few spores before 72 h, but spore counts increased from 72 h onwards and reached similar levels to strains 630Δ*erm* and 630Δ*erm* A+B- by the end of the experiment. The reduction in spore formation may in part be due to the observed reduction in OD as the 630E strains enter stationary phase, which might also explain their predilection to flocculate. Indeed comparing percentage sporulation (relative to vegetative cell count), confirmed the observation that 630Δ*erm* and 630Δ*erm* A+B- have a higher sporulation frequency than both 630E (and derivatives) and strain 630.

The germination of the 630E strains was also comparatively reduced and did not reach the same level as that of 630Δ*erm* and its progeny. At the last time point (240 min) strains 630E and 630E A+B- reach the same level of CFU/ml as strain 630. The observed delay could be due to the previously observed reduced cell growth of the 630E strains (**Fig. 3B**).

Toxin Production

Measurements of the amounts of toxin being produced by 630E and 630Δ*erm* and their derivatives were undertaken using both the *C. DIFFICILE TOX A/B II*™ ELISA assay kit from TechLab, measuring toxin A and B, and kits from TGCbiomics, specifically measuring either only toxin A or only toxin B. The results of the 72 h time point are shown in **Fig. 4**.

As shown in **Fig. 4A**, toxin production of 630, 630Δ*erm* or 630Δ*erm* A+B- clustered together, as did toxin production of 630E, 630E A+B- or 630E A+B- CT with the latter three showing no statistical differences between them ($P > 0.05$, one-way ANOVA with Fisher's LSD

test). There was, however, a statistically significant difference between the first three strains (630, 630Δ*erm* or 630Δ*erm* A+B-) and the second set of three strains (630E, 630E A+B- or 630E A+B- CT) ($P < 0.0001$). The *C. DIFFICILE TOX A/B II*™ ELISA does not differentiate between toxin A and B. In order to be able to quantify each toxin, the kits from TGCbiomics were used (**Fig. 4B and 4C**). The toxin A ELISA showed significantly higher production in strain 630Δ*erm* compared to 630E ($p<0.0016$) and also confirmed the previous observations that strains with impaired *tcdB*, produce more toxin A [8, 9] (**Fig. 4B**). No toxin B production was seen, as expected, in the *tcdB*-mutants. Strains 630 and 630Δ*erm,* however, both produced significantly more toxin B than 630E ($p<0.0001$) (**Fig. 4C**).

Whole genome sequencing

To establish whether strains 630E and 630Δ*erm*, and derivatives, contained any additional changes to the *ermB* gene deletion, relative to the parent strain 630, the following strains were sequenced using Next Generation Sequencing platforms: 630E A+B-, 630E A+B- CT on Illumina HiSeq (GATC, Germany) and 630Δ*erm* A-B on a Roche 454 (Deepseq, University of Nottingham, UK) and the data compared to the published genome of the parental strain 630 [12] and previously sequenced 630Δ*erm*Δ*pyrE*. [19] We used a frequency of 70% as a cut-off for SNP calling and found multiple SNPs, InDels and other minor changes, both common and unique to 630, 630E and 630Δ*erm*. In total, two SNPs in coding regions with non-synonymous changes were found that were common to all three strains (in CD630_11900, encoding an acyl-CoA N-acyltransferase where SNP changes phenylalanine133 to leucine and in CD630_13880, a pseudo gene where a frameshift is introduced). In addition to these, we found in both 630 and 630Δ*erm* strains three SNPs (two

184 in intergenic regions and one in a coding region of CD630_2667, encoding the BC domain of
185 a glucose PTS, changing valine228 to isoleucine). 630Δ*erm* had seven unique changes
186 compared to 630 and 630E (including six non-synonymous SNPs in coding regions), while
187 630E had eleven SNPs (with nine non-synonymous SNPs in coding regions) not found in the
188 other two strains. SNPs were confirmed by Sanger sequencing and thereafter by RNAseq
189 data (see below). Indeed, the SNPs found in the DNA-seq data were validated by using
190 the RNA-seq sequence reads mapped on the genome sequence with Bowtie2 [20] with each
191 position being checked using Tablet [21]. A complete list of SNPs and other small changes are
192 indicated in **Table 1** and in supplementary **Table S1**. During the preparation of this
193 manuscript a new sequence of 630 was published by Riedel *et al*. [22]. We incorporated their
194 data into **Table 1** (and **Table S1**). Overall this new sequence shows very few disparities to
195 the original one. However two SNPs found in our data were attributed to mistakes in the
196 original sequence (in CD630_17670 and CD630_31561). Another paper was recently
197 published by van Eijk *et al*., [23] resequencing 630Δ*erm*. Overall there are very few
198 discrepancies between their data and our findings, confirming the quality of both data sets.
199 We have incorporated their findings into **Table S1**.
200 It may be assumed, that during the repeated subculture of strain 630 undertaken in the
201 Mullany [13] and Rood [14] laboratories, sub-populations within the culture were isolated
202 carrying SNPs. However, it seems improbable that the two SNPs (**Table 1**), common to all
203 three strains, arose independently. Rather we hypothesise that these SNPs might be
204 sequencing mistakes. This theory gains weight through the new sequencing data by Riedel
205 *et al*. [22]. Two SNP changes which we identified originally between the published 630
206 sequence and our data were confirmed by Riedel et al to also be the sequence of their 630

seed stock. Unfortunately the genome announcement [22] does not state the exact source of their 630 strain. As mentioned above another three SNPs were only found in 630 and 630Δ*erm*, two of these are in intergenic regions which showed no expression in our RNAseq experiment, and the third is located in a PTS gene in 630 and 630Δ*erm* (position 3080703, Val_{228}Ile). Rather than having occurred independently it is more likely that these SNPs arose in the Mullany laboratory, subsequent to provision of chromosomal DNA to the Sanger Centre for determination of the 630 genome sequence [12], and before the strain 630 was passaged to obtain 630Δ*erm*. At the time, *C. difficile* strains in the Mullany laboratory were routinely stored at 4°C as Robertson's Cooked Meat stocks, as opposed to being frozen at -80°C in 10% glycerol (A.R. Roberts, personal communication). On this basis, the traditional microbiological practice of using Robertson's Cooked Meat to curate strains might not be ideal as strains are not entirely dormant and genome changes can occur over time. The SNPs that were found to be unique to 630Δ*erm* and 630E (n=8 and n=11, respectively) can be assumed to have been accrued at some point after the two 630 populations diverged, that is when the strain was sent to the Rood laboratory. It is most likely, although not certain, that the majority, if not all of the strain-specific SNPs arose during the repeated subculture experiments undertaken to isolate the *ermB* deletion strains 630E and 630Δ*erm*.

Changes specific to 630Δ*erm* include SNPs in three intergenic regions, which all have been determined with a coverage of over 150 and 100 % frequency (see **Table 1**). The other five changes comprise four non-synonymous SNPs and an insertion. The insertion has previously been reported by Rosenbusch *et al*.[24] and was confirmed by van Eijk *et al*. [23] and is an 18 bp duplication in *spo0A*, the master regulator of sporulation. This insertion might be responsible for the reduced sporulation frequency seen in strain 630 and also in 630E and

derivatives, which do not carry this duplication (which does not have this duplication) (**Fig. 3A**). The SNPs have been found in the following genes: CD630_08260, encoding a ferric uptake regulator (*perR* homologue) ($Thr_{41}Ala$); CD630_19070, encoding an alcohol dehydrogenase homologue (*eutG*) ($Gly_{252}Glu$); and CD630_35630, encoding a transcriptional regulator of the GntR family ($Ala_{91}Val$).

In contrast, strain 630E contains a larger number of non-synonymous SNPs including changes that result in nonsense mutations and in one case the inversion of a small segment of DNA preceding a flagella operon. We found two changes in intergenic regions, one with 100 % frequency and a coverage of 94 (position 3528736); the other at a much lower frequency (41 %), but confirmed a 150 bp inversion by Sanger sequencing in the promoter region of *flgB*, the first gene in a F3 flagella operon (early flagella genes). Non-synonymous SNPs were found in CD630_07610, encoding a putative RNA helicase ($Asp_{136}Tyr$); CD630_14040, encoding an oligopeptide transporter ($Glu_{536}Gly$); CD630_20270, encoding a hydrolase ($Gly_{373}Glu$); CD630_29430, encoding a phage replication protein ($Asn_{210}Asp$); and CD630_33790, encoding a conjugative transposon protein ($Glu_{63}Asp$). Finally, there is another SNP at position 3034953, in gene CD630_26270 ($Gly_{68}Cys$), encoding a conserved hypothetical protein. Interestingly the new genome sequence from Eijk et al. [23] suggested an “A” at position 3034953 in contrast to the earlier annotation suggesting “C”. The new annotation is in line with our RNAseq data (**Table S1**) and taken into account our sequencing data (**Table 1**) suggests that this is indeed a mutation in 630E and was miss-annotated in the original sequence. In one instance the nucleotide substitution resulted in the creation of a nonsense, stop codon, and as a consequence a severe, premature truncation of the encoding protein. Thus, the stop codon introduced into CD630_12740 encoding a topoisomerase I

(*topA*) homologue (Gln_{386}*) truncated the protein from 695 amino acids to 385 amino acids. Conversely, in the case of the glucose PTS operon *ptsG*-BC, the conversion of the stop codon of *ptsG-B* gene (CD630_26670) to a Glu codon ($*_{524}Glu$) resulted in its fusion to the coding region of the immediately downstream *ptsG-C* gene.

Virulence testing of 630Δ*erm,* 630E and mutants using an *in vivo* model

In order to confirm previous data and to rule out differences in experimental set up in different laboratories, the virulence of 630E and derivatives was assessed using the hamster infection model in our laboratory (University of Nottingham) as previously described. [9]

Figure 5 shows the times from infection to endpoint (in days) for the hamsters infected with 630E, 630E A+B- and 630E A+B- CT. For comparative purposes data for infection with 630Δ*erm* and 630Δ*erm* A+B- from a previous study [9] is also included. The latter emphasises the fact that all eight hamsters infected with strain 630Δ*erm* were colonised and succumbed to *C. difficile* disease (with an average time of 3.25 days from infection to endpoint). This is in direct contrast to what is observed with 630E where of the five animals successfully infected, only three were colonised till the respective endpoints and of these, two succumbed to disease (at day two and six). Two animals lost colonisation after days 15 and 18, respectively.

In our previous study [9] seven, of the eight animals infected with 630Δ*erm* A+B- (as also shown in **Fig. 5**), succumbed to disease with an average time to death of colonised hamsters being just under two days. One animal showed no signs of disease until the experimental endpoint, but was found not to have been colonised. Here of the 11 animals infected with the equivalent mutant of strain 630E (630E A+B-), only two animals succumbed to CDI (on day two and nine). Four animals in this group were never colonised, one lost colonisation

after day three and the others were colonised till endpoint. Six animals were infected with 630E A+B- CT, and of these two hamsters developed infection (day three and five). Two of the surviving animals lost colonisation after day 15 and 18 respectively. (**Fig. 5** and **Table S2**).

The difference between the average time to death of all hamsters administered 630Δ*erm* and 630Δ*erm* A+B- was found not to be statistically significant (one-way ANOVA, p=0.5355) (results from Kuehne *et al.* [9]). Similarly, the differences between the average times to death of all animals administered 630E, 630E A+B- and 630E A+B- CT was not statistically significant (one-way ANOVA, p=0.8919). In contrast, the difference between the 630Δ*erm* strain (and derivative) and the 630E strain (and derivatives) was statistically significant (one-way ANOVA, p>0.0001).

Correction of SNPs in strain 630E

In view of the large number of SNPs present in strain 630E, it was impractical to change them all back to the 630 parental sequence. We therefore selected just three specific mutations present in 630E and converted them back to the sequence present in the parental strain, 630.

Our principal target was to remove the stop codon from within the topoisomerase I gene, CD630_12740, as this enzyme plays a central role in the regulation of DNA negative supercoiling and its inactivation is likely to result in extensive pleiotropic effects. Indeed, in some bacteria its inactivation is lethal. [25-27] Moreover, bacterial genes related to pathogenesis and virulence have been shown to be sensitive to *topA* mutation in *E. coli,* [28] *S. flexneri,* [29] *Yersinia enterocolitica* [30] and *Salmonella*. [31] We therefore converted the "T" nucleotide at position 1480649 in 630E back to an "A" nucleotide, thereby removing the

299 nonsense stop codon and allowing the production of full length native topoisomerase
300 enzyme.

301 As a second target we elected to correct the inversion of DNA upstream of the F3 flagella
302 operon. As strain 630E is non-motile, and as the inverted region encompasses the non-
303 coding region immediately upstream of the *flgB* gene, it is likely to have disrupted the
304 promoter responsible for both *flgB* expression and the genes in the downstream operon.
305 The inversion is therefore likely to be the principal cause of the loss of motility in 630E.
306 Furthermore, factors affecting flagella expression can also influence toxin expression levels.
307 [32, 33]

308 Finally, we sought to correct the fusion of the two PTS components *ptsG-B* and *ptsG-C*, by
309 resurrection of the stop codon of *ptsG-B* through the conversion of the "C" nucleotide at
310 position 3079815 back to an "A" nucleotide. As glucose is known to affect toxin production,
311 through catabolite repression, [34, 35] it was reasoned that this particular SNP could be
312 affecting toxin expression, and therefore virulence.

313 The plasmids carrying the 630 wildtype alleles necessary for the correction of the three
314 targeted SNPs were assembled as described in Materials and Methods and then used to
315 effect the replacement of the 630E mutant alleles by allelic exchange. [15] To verify that the
316 mutant clones obtained were correct, each targeted region was amplified by PCR using
317 appropriate oligonucleotide primers and the DNA fragments obtained subjected to Sanger
318 sequencing on both DNA strands. In every case, clones carrying the desired 'corrected'
319 sequence were obtained. The new strains were named after the genes or regions that were
320 corrected, namely 630E_*topA*, 630E_CD2667 and 630E_*flgB*, respectively.

To assess the effects of the changes on the characteristics of the mutant strains, growth rate, sporulation and germination, motility, and *in vitro* cytotoxicity and toxin production (ELISA) were measured. None of the three corrected mutants exhibited any difference in growth rate compared to the parental strain 630E (data not shown). Similarly, sporulation and germination remained unaffected (data not shown). Toxicity testing revealed no difference to 630E using the *C. DIFFICILE TOX A/B II*™ ELISA assay kit from TechLab (**Fig. 4A**). To quantify toxin A and toxin B individually the ELISA kits from TGCbiomics were used to assay 630E_*topA* and 630E_CD2667 (**Fig. 4B**). No differences were measured for toxin A, but the strain 630E_*topA* showed significantly higher levels of toxin B than the parental strain 630E.

Transcriptomic comparison of 630, 630Δ*erm* and 630E

RNA was extracted from strains 630, 630Δ*erm* and 630E at 6, 14 and 24 h and used in an RNAseq experiment as described in Materials and Methods. The Principal Component Analysis (PCA) (**Fig. 6**) showed that strain 630Δ*erm* and 630E are closely correlated on a transcriptional level which is significantly separated from 630. While this result implies that both strains are fundamentally different to the parental strain, it does not indicate that the differences to 630 are the same for both strains. The analysis depicted by the Venn diagram (**Fig. 7**) confirms the results of the PCA, showing that the majority of differentially expressed genes are observed comparing 630Δ*erm* and 630E to 630. From a total of 1337 differentially expressed genes (**Table S3** contains all the genes differentially expressed along the growth and also comparisons between the strains), only 139 were common between all three

343 strains. A total of 345 were common between 630E and 630Δ*erm*, 60 were common
344 between 630 and 630Δ*erm* and 58 were common between 630 and 630E.

345 Most of the 345 genes differentially expressed in both, 630Δ*erm* and 630E, were either
346 up or down-regulated in the same way highlighting again how distinct the two strains are
347 from the parental strain 630 (**Table S3**). In TY medium used for the transcriptomic
348 experiments, known as a non-optimal for spore production, a total of 44 sporulation genes
349 were differentially expressed in both 630Δ*erm* and 630E, and all of these were
350 downregulated at 14 and 24 h compared to 6 h. No further differentially expressed
351 sporulation genes appeared in 630Δ*erm*, however, our analysis showed a further 22
352 sporulation genes, of which 21 were downregulated, in 630E. Amongst these was the master
353 regulator of sporulation *spo0A*. Nine genes classed as stress-related are differentially
354 expressed in all three strains (five upregulated), with a further three in 630 (all upregulated),
355 seven in 630Δ*erm* (four upregulated) and 16 in 630E (11 upregulated). Nine genes related to
356 secretion are down regulated in 630E and one gene related to type IV pili is upregulated. In
357 comparison only one secretion gene (putative pilus assembly ATPase) is differentially
358 expressed only in 630Δ*erm* (down regulated) and none in 630. Metabolism is also highly
359 differentially regulated in the three strains. 90 genes were uniquely, differentially expressed
360 in 630E, 50 in 630Δ*erm* and 30 in 630. In particular the amino acid metabolism stands out
361 for 630E with the majority of genes being downregulated. (**Table S3**).

362 RNAseq data can be used to independently corroborate genome re-sequencing data.
363 Thus, it was apparent that those changes identified by CLC Bio as being present with a
364 frequency of 70% or less, except for CD630_20102, were not real accordingly to the RNAseq
365 analysis (**Table S1**). This increases the confidence in disregarding changes identified by NGS

366 with a low frequency. In most cases, the SNPs and Indels identified by NGS were confirmed
367 by the RNAseq analysis, with the following exceptions: for SNPs in 630E we found two
368 disagreements notably in CD630_33790 and CD630_29430, which both had 100 % frequency
369 and a high coverage (around 200 reads) in the DNA sequence analysis, but only low coverage
370 in the RNAseq experiment. Due to the low coverage of these regions during the RNAseq
371 experiment, which is indicative of low or no expression under the examined conditions, a
372 sequencing error cannot be excluded. For the SNP in CD630_12740 the RNA coverage
373 corroborated the genomic data for 630E, but was in disagreement with the genomic data
374 for 630 and 630Δ*erm*. For three SNPs in 630Δ*erm* similar scenarios were observed.
375 CD630_19070 had very low RNA coverage, CD630_35650 showed ambiguous RNA data with
376 low coverage for 630E. CD630_08260, the *perR* homologue, had convincing DNA data, with
377 frequencies of 98-100 % and coverage of at least a 100 which was corroborated for 630Δ*erm*
378 by RNAseq coverage.
379 In terms of actual expression data (**Table S1**), CD630_07610 (the RNA helicase),
380 CD630_14040 (oligopeptide transporter), CD630_20270 (hydrolase) and CD630_29430
381 (phage replication protein) all showed differential expression in 630E compared to the other
382 two strains, with the first two showing reduced expression and the latter two an increase.
383 CD630_29430, however, also showed an increase in expression in 630 at the later time point.
384 Changes in CD630_26670 in 630Δ*erm* and 630E both seem to lead to severely reduced
385 expression. CD630_12740 (*topA*) only showed differential expression at 24 h in 630Δ*erm* and
386 CD630_12140 (*spo0A*) expression was severely reduced in 630E.
387

388 ## Discussion

389 Previously, two studies [8,9] have attempted to use isogenic mutants defective in the
390 production of either toxin A or toxin B to determine the relative importance of these two
391 virulence factors in CDI using the hamster infection model. However, despite generating
392 essentially equivalent A+B-insertion mutants in ostensibly the same strain of *C. difficile*
393 (630), contradictory outcomes were obtained in terms of the importance of toxin A. Thus, a
394 *tcdB* mutant created in the one study [8] producing only TcdA did not cause disease in the
395 hamster, whereas the equivalent ClosTron mutant made in our laboratory (Minton group) [9]
396 remained virulent. The work undertaken here has provided compelling evidence that the
397 reason for the observed conundrum resides in the use of two different erythromycin-
398 sensitive derivatives of strain 630.
399 Here we have shown that both erythromycin-sensitive derivatives, 630E [14] and 630Δ*erm*
400 [13] carry a significant number of SNPs compared to the published sequence. Moreover, it is
401 clear that whilst the phenotypic properties of 630Δ*erm* and its mutant derivatives closely
402 resemble that of the parent strain 630, strain 630E and its progeny exhibit substantive
403 differences. Thus, whereas latter strains exhibit reduced growth rates, are less proficient in
404 spore formation and are non-motile, 630Δ*erm* strains mirror the behaviour of the 630
405 parental strain with respect to these phenotypes. Furthermore, 630E strains produce
406 reduced amounts of toxin and both struggle to colonise hamsters, and once colonised,
407 animals are less likely to succumb to disease. In short, 630E and its derivatives (i.e., 630E A-
408 B+ and 630E A+B- CT) are less virulent than 630Δ*erm* and its mutant counterparts (i.e.,
409 630Δ*erm* A+B-).
410 The altered properties of 630E and its derivatives are undoubtedly a consequence of
411 the observed SNPs. However, the substantive number of changes involved makes it difficult

412 to assign any particular SNP to a specific alteration in the observed phenotype, particularly
413 as a combination of mutagenic changes could be responsible. Whilst it is now possible to
414 make precise changes to the genome using allelic exchange methodologies [15] it is not
415 practically feasible to make all of the sequential rational changes needed to definitively
416 identify the mutation(s) responsible for a particular phenotype. As such, we only corrected
417 three specific SNPs that we reasoned may be making a significant contribution. The
418 outcomes of these experiments only emphasised the difficulty of such an undertaking, and
419 served to highlight the dangers involved in making assumptions. Thus, whilst it seemed
420 reasonable to assume that the DNA inversion within the promoter region of the flagella
421 operon was likely to have caused the observed non-motile phenotype, this surprisingly
422 proved not to be the case. Re-inversion of the 150 bp region failed to restore motility. Clearly
423 other SNPs are at least partly responsible for the observed lack of motility. Singling out any
424 other SNP as the culprit would in the absence of experimental evidence be
425 counterproductive.

426 Equally negative was the observed outcome of correcting the mutation in CD630_12740
427 that results in a truncation of the encoded topoisomerase I enzyme. Given this enzyme
428 controls DNA supercoiling, and given that its mutation in certain bacteria is either a lethal
429 event [25-27] and/or is involved in the regulation of virulence factors, [28-30] it seemed likely that
430 its presence would result in pleiotropic effects that could have contributed to the observed
431 phenotypic changes. However, its correction, with the exception of a measurable increase
432 in toxin B levels, seemingly had no effects on the behaviour of the strain, at least for those
433 properties measured. The reasons are not clear. In other bacteria, mutations of *topA* are
434 only isolated if compensatory mutations arise elsewhere in the genome. [26] Whether any of

435 the other SNPs present in 630E (eg., the RNA helicase mutation) are negating the effects of
436 the TopA truncation is currently unknown.

437 To understand the differences observed further, we analysed the transcriptome of 630,
438 630Δ*erm* and 630E, comparing expression at 6 h to 14 h and to 24 h (**Table S3**). The data
439 corroborated the phenotypic analysis, showing vastly different transcriptomes for all three
440 strains. While 630E and 630Δ*erm* cluster together in the PCA (**Fig. 6**), this only highlights how
441 different the two strains really are from the progenitor. The analysis clearly shows that the
442 three strains are very different from each other and also serves as an explanation as to why
443 the change of a single SNP could not restore any given phenotype. Overall 630E seems the
444 most divergent with many genes differentially expressed involved in metabolism and
445 regulation (**Table S3**). Additionally 32 genes grouped under the descriptor 'cell factor', many
446 of which play a role in energy metabolism, are differentially expressed in 630E, with only six
447 of these being upregulated. In contrast out of 19 genes in 630, 11 are upregulated and, out
448 of 10 in 630Δ*erm,* six were upregulated. The number of genes downregulated in energy
449 metabolism in 630E might relate to the growth differences seen between the strains.

450 Interestingly 22 genes involved in sporulation are differentially expressed, 21 of these
451 downregulated, in 630E versus one in 630 and two in 630Δ*erm*. This is consistent with the
452 observed delay in sporulation and reduced amount of spores produced by 630E. Secretion
453 also seems most affected in 630E, with 10 genes differentially expressed, compared to none
454 in 630 and one in 630Δ*erm*. A general defect in secretion could affect the secretion of certain
455 virulence or adhesion factors. Furthermore, 33 cell wall genes are differentially expressed in
456 630E (compared to 14 each in 630Δ*erm* and 630). This may also contribute to the observed
457 colonisation deficiencies. Mobile elements are, however, more differentially transcribed in

630 and 630Δ*erm* (15 each) versus 630E (nine). As in many cases different pathways were affected, we propose that this could at least in part explain the different adaptability and virulence of the two strains. In both strains many regulators were differentially affected providing a further basis for the observed phenotypic variation between strains.

Conclusion

Our study has established that the parental strains (630E and 630Δ*erm*) used in the two previous studies, that explored the relative roles of toxin A and toxin B in disease, [8, 9] are phenotypically and genetically distinct. Here we also reveal that the three strains (630, 630Δ*erm* and 630E) have vastly different transcriptomes, which no doubt lead to the different phenotypes observed. This immense diversity also underlines our finding that by restoring just one SNP, the entire transcriptome cannot be changed. The presence of SNPs in strain 630E significantly affects its transcriptome which in turn has a significant impact on growth, sporulation and finally virulence of this strain in the hamster model of infection under the conditions tested. Data (such as motility, toxicity and virulence) obtained with strain 630Δ*erm* reflects more accurately the behaviour of the parent strain 630. As such, it may be concluded that 630 producing toxin A alone will cause disease in the hamster. As a consequence, toxin A should remain a target for the rational development of effective countermeasures against *C. difficile.*

This study has also highlighted a number of issues that need to be borne in mind in the future. At a specific level, if researchers wish to undertake genetic-based studies with strain 630, then the use of strain 630Δ*erm* should be favoured over strain 630E. At a more fundamental level, researchers need to effectively curate their strains to prevent the

inadvertent isolation of SNPs. Ideally, master seed banks need to be established as frozen glycerol stocks. Moreover, the genome of the stored strain should be re-sequenced as part of the storage process whenever a strain is received from external sources, regardless of whether it has been re-sequenced in the sending laboratory.

Materials and Methods

Bacterial strains and routine culture conditions

Bacterial strains and plasmids used in this study are listed in **Table 2**. *E. coli* was cultured aerobically at 37°C with shaking at 200 rpm in LB medium with chloramphenicol supplementation (25 µg/ml) where appropriate. *C. difficile* was cultured in TY (tryptose yeast) medium supplemented with thiamphenicol (15 µg/ml) where appropriate. When needed, *C. difficile s*trains were plated on BHIS agar (Brain Heart Infusion agar [Oxoid] supplemented with 5 mg/ml yeast extract [Oxoid] and 0.1% [wt/vol] cysteine [Calbiochem]) supplemented with d-cycloserine (250 µg/ml), cefoxitin (8 µg/ml) [Oxoid] (BHIScc). Fluorocytosine selections were carried out on *C. difficile* minimal medium (CDMM) as described previously. [15] All *C. difficile* cultures were incubated at 37°C anaerobically in an anaerobic MACS1000 workstation (Don Whitley, Yorkshire, UK).

Mutant nomenclature

For the sake of simplicity, *C. difficile* strains that carried a *tcdA* insertional mutant were referred to as A-, those carrying a *tcdB* mutant as B-, and those strains carrying a mutation in both genes as A-B-. To avoid any ambiguity, if the gene was not inactivated it was referred to as A+ or B+, as appropriate. Thus, a *tcdA* mutant of 630Δ*erm* constructed using ClosTron technology as described, [9, 16] was designated 630Δ*erm* A-B+. The equivalent mutant in 630E

504 constructed through the insertion of a replication-deficient plasmid, according to the
505 method of O'Connor et al., [14] was designated 630E A-B+. When ClosTron technology was
506 used in 630E, this was clarified by adding a 'CT' suffix, 630E A-B+CT to the strain designation.
507
508 **Whole genome sequencing and bioinformatics**
509 Genomic DNA from strains 630E A+B-, 630E A+B-CT and 630Δ*erm* A+B- was prepared by
510 phenol:chloroform extraction. 630E A+B-, 630E A+B-CT, 630Δ*erm*(Δ*pyrE*) were sequenced
511 on Ilumina highseq (GATC, Germany) and 630Δ*erm* A+B- on a Roche 454 (Deepseq,
512 Nottingham, UK) and the data compared to the published genome of 630 [11,19] using CLC
513 genomic workbench. All raw sequencing data have been deposited in the sequence read
514 archive (SRA) under the study name PRJNA304508. The accession number is SRP066836. The
515 sequencing data for 630Δ*erm*Δ*pyrE* had been obtained previously [19] and with no additional
516 changes, other than the *pyrE* deletion, present compared to 630Δ*erm*, were used to analyse
517 the parental strain 630Δ*erm*. We used a frequency of 70% as a cut-off for SNP calling. SNPs,
518 InDels and inversions were confirmed by amplifying a few hundred base pairs up- and
519 downstream of the area of interest (primers are listed in **Table S4**) and the amplicon was
520 Sanger sequenced (Source BioScience, UK). This confirmation was done on all strains
521 including the parental strains (630, 630Δ*erm*, 630E) and the derivatives (630Δ*erm* A+B-, 630E
522 A+B-, 630E A+B-CT).
523
524 **Correction of SNPs and reversal of 150-bp region within the flagellar operon**
525 Using the method described by Cartman et al. [15] we "corrected" the two SNPs and an
526 inversion in 630E to the 630Δ*erm* genotype. A stretch of DNA corresponding to

527 approximately 500 bp either side of the area to be altered was synthesised by Biomatik and
528 cloned into plasmid pMTL-SC7315λ2.3. This vector was transformed by electroporation into
529 *E. coli* CA434 cells [36] and subsequently conjugated into 630E. Single crossover colonies were
530 identified as those growing faster on plates containing thiamphenicol. Following overnight
531 incubation on CDMM containing 5-fluorocytosine, colonies were incubated on BHIScc plates
532 with and without thiamphenicol. Those strains that had lost the plasmid (both wildtype and
533 double crossover) were unable to grow on thiamphenicol. SNP corrections were confirmed
534 by PCR (Primers see **Table S4**) and Sanger sequencing (Source BioScience, UK).
535
536 **ClosTron mutagenesis**
537 A *tcdB* mutant was generated in the 630E background according to the published
538 method, [16] using the same plasmid that was used to generate the equivalent mutant in
539 630Δ*erm*. [9] This newly created strain was referred to as 630E A+B- CT.
540
541 **Southern and Western blot**
542 The Southern and Western blot were performed as described in Kuehne et al., 2010. [9]
543
544 ***In vivo* testing of mutants**
545 *In vivo* testing was carried out in Syrian Golden hamsters (Charles River, Germany) as
546 previously described. [9] Briefly, clindamycin was administered orally on day -five to render
547 the animals susceptible to infection. On day zero, 10,000 spores were administered orally.
548 Animals were assessed for signs of CDI (weight loss, wet tail, lethargy, lack of response to
549 stimulus) six times a day for the first five days, and once daily for the following 14 days. At

this point animals that failed to display signs of CDI were euthanised. Faecal pellets were collected daily from day zero to endpoint, homogenised and plated on *C. difficile* fructose agar (CDFA). *C. difficile* colonies were sub-cultured onto BHIS agar and the genotype was established by PCR (primers in **Table S4**) followed by Sanger sequencing (results in **Table S2**). At the experimental endpoint, part of the caecum of each animal was collected. This was also used to plate on CDFA to verify colonisation.

***In vitro* testing of mutants**

Growth curves: To assess the effects of SNPs and "corrected" SNPs/inversion on the growth characteristics of all strains, we performed growth curve experiments over 24 h. A 180 µL volume of TY medium was inoculated with 20 µL of an overnight culture in 96-well plates and incubated for 24 h in a GloMax-Multi Microplate Multimode Reader (Promega, USA). Samples were shaken every h and OD_{600} measurements were taken immediately after.

Motility assays: 2xYTG (tryptone (1.6%), yeast (1%), NaCl (0.4%), Gelzan (0.24%)[Sigma-Aldrich] and glucose (0.5%)) agar was utilised. 25 mL were poured into each petri dish and let to solidify at room temperature for 15 min. The plates were then dried at 37°C for 30 min. The plates were placed into the anaerobic cabinet 24 h before use. 2 µL volumes of overnight culture were 'dropped' onto each plate. Plates were incubated anaerobically for 48 h. Motility was assessed by eye and the plates photographed.

Sporulation and germination assays: Sporulation and germination assays were carried out as previously described. [17, 18] Briefly, for the sporulation assay cultures were grown for five days, with 2 X 500 µl samples taken at 0, 24, 48, 72, 96 and 120 h. One sample from each time point was heated to 65°C for 30 min while the other sample was kept at room

573 temperature. After this time, samples were serially diluted from 10^0 to 10^{-7} in PBS. 3 X 20µl
574 of each dilution was spotted onto BHIS plates containing 0.1% taurocholic acid and were
575 incubated for 24 h. The following day, colonies were counted and CFU/mL were calculated.
576 A 630Δ*erm spo0A*::CT mutant strain (containing a ClosTron insertion in the *spo0A* gene [37]),
577 which is unable to form spores, was used as a negative control.
578 Germination was measured as a function of the ability of a germinated spore to outgrow
579 in the absence of taurocholate. Spore stocks were prepared as previously described by Heeg
580 *et al*., 2012 [38] and stored at -20°C. The optical density of spore suspensions (OD_{600}) was
581 adjusted to 1.0 and 450 µl was used per measurement. This equated to approximately 2.5 X
582 10^7 spores. Spore suspensions were heat treated at 60°C for 25 min to kill any remaining
583 vegetative cells and then centrifuged and resuspended in BHIS with the germinant
584 taurocholic acid (0.1%) in a total volume of 20 ml. Samples were taken at 5, 10, 20, 30, 60,
585 90, 120, 180 and 240 min, briefly centrifuged, washed and resuspended in phosphate-
586 buffered saline (PBS), the samples were then diluted and plated on plain BHIS agar. Plates
587 were incubated for 24 h before the CFUs were enumerated. Colonies that grew on these
588 plates were considered to be germinated vegetative bacteria.
589
590 **Toxin A/B ELISA:** ELISA assays were performed using the *C. DIFFICILE TOX A/B II*™ kit from
591 TechLab and the TGC-E002-1-separate detection of *C. difficile* toxins A and B kit from
592 TGCbiomics according to the manufacturers' instructions. Cultures of *C. difficile* were grown
593 in TY medium without glucose for 72 h, at which time 1 ml samples were taken, centrifuged
594 and the supernatant filter-sterilised and used for the ELISAs. A 1:2 dilution was used for the
595 toxin B ELISA kit from TGCbiomics. To quantify toxins a standard curve with pure toxin (the

native antigen company) was established for the TechLab ELISA and also Toxin A ELISA from TGCbiomics.

RNAseq: Total RNA was extracted from 2 independent biological replicates of 630, 630Δ*erm* and 630E strains at 3 time points (18 samples). Bacteria were grown in TY broth medium after 6, 14 and 24 h as previously described. [35] The mRNA was treated with MicrobExpress kit (Ambion). For oriented RNA-seq library construction, the Truseq stranded RNA seq Illumina kit was used according to manufacturer's instructions before sequencing using the Illumina HiSeq 2500 machine. Sequencing reads were mapped using Bowtie [39] to the reannotated 630 reference genome [40] complemented with the known ncRNA. [41] Statistical analyses were performed on each strand coverage count with DESeq2 [42] using the 6 h value as a reference for reporting the expression data of 14 and 24 h. A gene was considered differentially expressed when the fold change was > 2 and the *P value* was < 0.05.

The RNA-seq data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus database under the accession no. GSE72006

RNA-seq coverage visualization is available through the COV2HTML software: [43]

630	14H - 6H	http://mmonot.eu/COV2HTML/visualisation.php?str_id=-20
	24H - 6H	http://mmonot.eu/COV2HTML/visualisation.php?str_id=-22
630Δ*erm*	14H - 6H	http://mmonot.eu/COV2HTML/visualisation.php?str_id=-24
	24H - 6H	http://mmonot.eu/COV2HTML/visualisation.php?str_id=-26
630E	14H - 6H	http://mmonot.eu/COV2HTML/visualisation.php?str_id=-28
	24H - 6H	http://mmonot.eu/COV2HTML/visualisation.php?str_id=-30

Graphs and statistical analyses

All graphs were generated and statistical analyses were performed using GraphPad PRISM 6.02. Statistical analysis comprised either 2-way ANOVA for multiple comparisons or unpaired t test for pairwise comparisons. All experiments were carried out in triplicate unless stated otherwise.

Ethics statement

This work was reviewed and approved locally by the Animal Welfare and Ethical Review Body (formerly the Ethical Review Committee) at the University of Nottingham and performed under a project licence (PPL 40/3590) granted under the Animal (Scientific Procedures) Act, 1986, by the UK Home Office. The work was performed in accordance with the NC3R^{s} ARRIVE guidelines. [44]

Acknowledgement

We would like to thank Haitham Hussain for providing *C. difficile* 630*Δerm,* Dena Lyras for providing *C. difficile* 630E and toxin mutants and Rory Cave for helping with PCRs and Sanger sequencing. We would also like to acknowledge Sean Roberts who was involved in creating the 630E A+B- CT strain. This work was supported by the UK Medical Research Council (grant number G0601176) and a Merck Investigator Studies Program award (grant number MISP#39245). The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Limited or the Medical Research Council (UK).

References

1. Govind R, Dupuy B. Secretion of *Clostridium difficile* toxins A and B requires the holin-like protein TcdE. PLoS Pathogens 2012; 8:e1002727.

2. Jank T, Giesemann T, Aktories K. Rho-glucosylating *Clostridium difficile* toxins A and B: new insights into structure and function. Glycobiology 2007; 17:15R-22R.
3. Sun X, Savidge T, Feng H. The enterotoxicity of *Clostridium difficile* toxins. Toxins (Basel) 2010; 2:1848-80.
4. Lyerly DM, Krivan HC, Wilkins TD. *Clostridium difficile*: its disease and toxins. Clinical Microbiology Reviews 1988; 1:1-18.
5. Lyerly DM, Barroso LA, Wilkins TD, Depitre C, Corthier G. Characterization of a toxin A-negative, toxin B-positive strain of *Clostridium difficile*. Infection Immunity 1992; 60:4633-9.
6. Kim J, Pai H, Seo MR, Kang JO. Clinical and microbiologic characteristics of tcdA-negative variant *Clostridium difficile* infections. BMC Infectious Diseases 2012; 12:109.
7. Chaves-Olarte E, Low P, Freer E, Norlin T, Weidmann M, von Eichel-Streiber C, Thelestam M. A novel cytotoxin from *Clostridium difficile* serogroup F is a functional hybrid between two other large clostridial cytotoxins. Journal of Biological Chemistry 1999; 274:11046-52.
8. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, et al. Toxin B is essential for virulence of *Clostridium difficile*. Nature 2009; 458:1176-9.
9. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in *Clostridium difficile* infection. Nature 2010; 467:711-3.
10. Monot M, Eckert C, Lemire A, Hamiot A, Dubois T, Tessier C, Dumoulard B, Hamel B, Petit A, Lalande V, et al. *Clostridium difficile*: New Insights into the Evolution of the Pathogenicity Locus. Science Reports 2015; 5:15023.
11. Kuehne SA, Cartman ST, Minton NP. Both, toxin A and toxin B, are important in *Clostridium difficile* infection. Gut Microbes 2011; 2:252-5.
12. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeno-Tarraga AM, Wang H, et al. The multidrug-resistant human pathogen *Clostridium difficile* has a highly mobile, mosaic genome. Nature Genetics 2006; 38:779-86.
13. Hussain HA, Roberts AP, Mullany P. Generation of an erythromycin-sensitive derivative of *Clostridium difficile* strain 630 (630Delta*erm*) and demonstration that the conjugative transposon Tn*916*DeltaE enters the genome of this strain at multiple sites. Journal of Medical Microbiology 2005; 54:137-41.
14. O'Connor JR, Lyras D, Farrow KA, Adams V, Powell DR, Hinds J, Cheung JK, Rood JI. Construction and analysis of chromosomal *Clostridium difficile* mutants. Molecular Microbiology 2006; 61:1335-51.
15. Cartman ST, Kelly ML, Heeg D, Heap JT, Minton NP. Precise manipulation of the *Clostridium difficile* chromosome reveals a lack of association between the *tcdC* genotype and toxin production. Applied and Environmental Microbiology 2012; 78:4683-90.
16. Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP. The ClosTron: Mutagenesis in *Clostridium* refined and streamlined. Journal of Microbiological Methods 2010; 80:49-55.
17. Burns DA, Heap JT, Minton NP. SleC is essential for germination of *Clostridium difficile* spores in nutrient-rich medium supplemented with the bile salt taurocholate. Journal of Bacteriology 2010; 192:657-64.
18. Burns DA, Heeg D, Cartman ST, Minton NP. Reconsidering the sporulation characteristics of hypervirulent *Clostridium difficile* BI/NAP1/027. PLoS One 2011; 6:e24894.

19. Ng YK, Ehsaan M, Philip S, Collery MM, Janoir C, Collignon A, Cartman ST, Minton NP. Expanding the repertoire of gene tools for precise manipulation of the *Clostridium difficile* genome: allelic exchange using *pyrE* alleles. PLoS One 2013; 8:e56051.
20. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature Methods 2012; 9:357-9.
21. Milne I, Stephen G, Bayer M, Cock PJ, Pritchard L, Cardle L, Shaw PD, Marshall D. Using Tablet for visual exploration of second-generation sequencing data. Brief Bioinform 2013; 14:193-202.
22. Riedel T, Bunk B, Thurmer A, Sproer C, Brzuszkiewicz E, Abt B, Gronow S, Liesegang H, Daniel R, Overmann J. Genome Resequencing of the Virulent and Multidrug-Resistant Reference Strain *Clostridium difficile* 630. Genome Announcements 2015; 3.
23. van Eijk E, Anvar SY, Browne HP, Leung WY, Frank J, Schmitz AM, Roberts AP, Smits WK. Complete genome sequence of the *Clostridium difficile* laboratory strain 630Deltaerm reveals differences from strain 630, including translocation of the mobile element CTn5. BMC Genomics 2015; 16:31.
24. Rosenbusch KE, Bakker D, Kuijper EJ, Smits WK. *C. difficile* 630Delta*erm* Spo0A regulates sporulation, but does not contribute to toxin production, by direct high-affinity binding to target DNA. PLoS One 2012; 7:e48608.
25. Ahmed W, Menon S, Godbole AA, Karthik PV, Nagaraja V. Conditional silencing of topoisomerase I gene of *Mycobacterium tuberculosis* validates its essentiality for cell survival. FEMS Microbiology Letters 2014; 353:116-23.
26. Stupina VA, Wang JC. Viability of *Escherichia coli topA* mutants lacking DNA topoisomerase I. The Journal of Biological Chemistry 2005; 280:355-60.
27. Suerbaum S, Brauer-Steppkes T, Labigne A, Cameron B, Drlica K. Topoisomerase I of *Helicobacter pylori*: juxtaposition with a flagellin gene (*flaB*) and functional requirement of a fourth zinc finger motif. Gene 1998; 210:151-61.
28. Tessier MC, Graveline R, Crost C, Desabrais JA, Martin C, Drolet M, Harel J. Effects of DNA supercoiling and topoisomerases on the expression of genes coding for F165(1), a P-like fimbriae. FEMS Microbiology Letters 2007; 277:28-36.
29. Ni Bhriain N, Dorman CJ. Isolation and characterization of a *topA* mutant of *Shigella flexneri*. Molecular Microbiology 1993; 7:351-8.
30. Darwin AJ, Miller VL. Identification of *Yersinia enterocolitica* genes affecting survival in an animal host using signature-tagged transposon mutagenesis. Molecular Microbiology 1999; 32:51-62.
31. Galan JE, Curtiss R, 3rd. Expression of *Salmonella typhimurium* genes required for invasion is regulated by changes in DNA supercoiling. Infection and Immunity 1990; 58:1879-85.
32. Aubry A, Hussack G, Chen W, KuoLee R, Twine SM, Fulton KM, Foote S, Carrillo CD, Tanha J, Logan SM. Modulation of toxin production by the flagellar regulon in *Clostridium difficile*. Infection and Immunity 2012.
33. Baban ST, Kuehne SA, Barketi-Klai A, Cartman ST, Kelly ML, Hardie KR, Kansau I, Collignon A, Minton NP. The Role of Flagella in *Clostridium difficile* Pathogenesis: Comparison between a Non-Epidemic and an Epidemic Strain. PLoS One 2013; 8:e73026.
34. Antunes A, Martin-Verstraete I, Dupuy B. CcpA-mediated repression of *Clostridium difficile* toxin gene expression. Molecular Microbiology 2011; 79:882-99.

730 35. Antunes A, Camiade E, Monot M, Courtois E, Barbut F, Sernova NV, Rodionov DA,
731 Martin-Verstraete I, Dupuy B. Global transcriptional control by glucose and carbon regulator
732 CcpA in *Clostridium difficile.* Nucleic Acids Research 2012; 40:10701-18.
733 36. Williams DR, Young DI, Young M. Conjugative plasmid transfer from *Escherichia coli*
734 to *Clostridium acetobutylicum*. Journal of General Microbiology 1990; 136:819-26.
735 37. Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP. The ClosTron: a universal
736 gene knock-out system for the genus *Clostridium*. Journal of Microbiological Methods 2007;
737 70:452-64.
738 38. Heeg D, Burns DA, Cartman ST, Minton NP. Spores of *Clostridium difficile* clinical
739 isolates display a diverse germination response to bile salts. PLoS One 2012; 7:e32381.
740 39. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient
741 alignment of short DNA sequences to the human genome. Genome Biology 2009; 10:R25.
742 40. Monot M, Boursaux-Eude C, Thibonnier M, Vallenet D, Moszer I, Medigue C, Martin-
743 Verstraete I, Dupuy B. Reannotation of the genome sequence of *Clostridium difficile* strain
744 630. Journal of Medical Microbiology 2011; 60:1193-9.
745 41. Soutourina OA, Monot M, Boudry P, Saujet L, Pichon C, Sismeiro O, Semenova E,
746 Severinov K, Le Bouguenec C, Coppee JY, et al. Genome-wide identification of regulatory
747 RNAs in the human pathogen *Clostridium difficile*. PLoS Genetics 2013; 9:e1003493.
748 42. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion
749 for RNA-seq data with DESeq2. Genome Biology 2014; 15:550.
750 43. Monot M, Orgeur M, Camiade E, Brehier C, Dupuy B. COV2HTML: a visualization and
751 analysis tool of bacterial next generation sequencing (NGS) data for postgenomics life
752 scientists. Omics 2014; 18:184-95.
753 44. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience
754 research reporting: The ARRIVE guidelines for reporting animal research. Journal of
755 Pharmacology and Pharmacotherapy 2010; 1:94-9.
756
757
758

Figure legends

Figure 1. Growth curves of strain 630 and its derivatives. A. 630 (630), 630Δ*erm* and 630E were grown in TY-broth for 24 h in a 96 well plate reader. The optical density at 600 nm was measured every 30 min. B. This graph shows the same growth as A. and in addition the growth of derivatives 630Δ*erm* A+B-, 630E A+B- and 630E A+B- CT.

Figure 2. Motility assays. The assay was carried out by inoculating overnight cultures onto motility agar plates and incubating anaerobically for 48 h. Strains 630, 630Δ*erm* and 630E were compared for their ability to swarm.

Figure 3. Sporulation and Germination. A. Sporulation over 120 h comparing heat treated CFUs of strains 630, 630Δ*erm,* 630Δ*erm* A+B-, 630E, 630E A+B- and 630E A+B- CT with a non-sporulating control (*spo0A*). B. The extent of germination of the indicated strains was measured over 250 min as the ability of germinated spores to form colonies on plates lacking taurocholate.

Figure 4. Toxin ELISAs. A. The *C. DIFFICILE TOX A/B II*™ ELISA assay kit from TechLab was used to measure combined toxin A and B in strains 630, 630Δ*erm,* 630Δ*erm* A+B-, 630E, 630E A+B-, 630E A+B- CT, 630E_*topA*, 630E_*flgB* and 630E_CD2667 grown in TY for 72 h. B. and C. Toxin ELISAs TGCbiomics, measuring the toxins separately were used to quantify toxin A (B) and toxin B (C) produced by strains 630, 630Δ*erm,* 630Δ*erm* A+B-, 630E, 630E A+B- and 630E A+B- CT grown in TY for 72 h. Statistics were performed using one-way ANOVA with Fisher's LSD test.

Figure 5. Infection to endpoint in the Hamster infection model. Groups of Golden Syrian Hamsters were challenged with *C. difficile* 630E (5 hamsters), 630E A+B- (11 hamsters) and 630E A+B- CT (6 hamsters). The graph represents the time from inoculation to endpoint. The maximal duration of the experiment was set to 20 days. Animals represented in open symbols, have not been colonized despite challenge or lost colonization before day 20. Details can be seen in **Table 1**. The dotted line separates this experiment from data obtained by Kuehne et al. [9], which are represented here as a comparator. In that study 8 hamsters were infected with *C. difficile* 630Δ*erm* and another 8 hamsters with 630Δ*erm* A+B-.

Figure 6. Principal Component Analysis (PCA). The Principal Component Analysis (PCA) visualizes the variance of the data in a single graph. The axis represent the two largest variances of the data; PC1 accounts for 42% and PC2 accounts for 21%, that means that 63% of the total variance of the dataset is explained in this graph. The third component accounts for less than 10% and further components have a value that falls rapidly. The PCA represents the RNAseq data (at three different time points, six, 14 and 24 h) in duplicate for 630 (blue), 630Δ*erm* (green) and 630E (orange). The different time points are represented as dots in the different shades of the respective colour as indicated in the colour legend.

Figure 7. Venn Diagram representing differentially expressed genes in the three different strains. The diagram summarises the output from the RNAseq data, comparing strains 630, 630Δ*erm* and 630E. It depicts all differentially expressed genes and shows how many genes are differentially expressed in all strains, in two of the strains or are unique to just one strain.

Table 1. Single Nucleotide Polymorphisms (SNPs) and other changes found after re-sequencing.

Gene	Description	Position	630 [12]	630 [22]	630	C	F	630Δ*erm*	C	F	630E	C	F	AA
630E														
CD630_07610	Putative ATP-dependent RNA helicase	933139	G	-	-			-			T	199	100	Asp136Tyr
CD630_14040	Putative oligopeptide transporter	1626977	A	-	-			-			G	187	100	Glu536Gly
CD630_20270	N-carbamoyl-L-amino acid hydrolase	2339506	G	-	-			-			A	73	100	Gly373Glu
CD630_26670	PTSG-BC	3079815	A	-	-			-			C	165	100	*524Glu
CD630_26270	Hypothetical protein	3034953	C	A	A			A			-	156	100	Gly68Cys
CD630_33790	conjugative transposon protein	3951559	C	-	-			-			A	307	100	Glu63Asp
CD630_12740	*topA*	1480649	C	-	-			-			T	146	100	Gln386*
CD630_29430	Putative phage replication protein	3422569	T	-	-			-			C	195	100	Asn210Asp
IG	Intergenic region	309208	-	-	-			-			INV	129	41	
IG	Intergenic region	3528736	G	-	-			-			T	94	100	
630Δ*erm*														
CD630_19070	*eutG*	2209236	G	-	-			A	127	97				Gly252Glu
CD630_35650	GntR family transcriptional regulator	4166495	G	-	-			A	182	100	-			Ala91Val
IG	Intergenic region	2937176	C	-	-			A	173	100	-			
IG	Intergenic region	3005866	T	-	-			G	156	100	-			
IG	Intergenic region	3591103	G	-	-			A	211	100	-			
CD630_12140	*spo0A*	1413057	-	-	-			AGAATGTAGGAAATATAG	112	40	-			Insertion
CD630_08260	Ferric uptake regulator	1000995	A	-	-	100	100	G	153	100	-	170	98	Thr41Ala
630														
CD630_32450	*prdR*	3797112	C	-	T	117	100	-			-			Glu261Lys

CD630_02050	Transcription antiterminator, PTS operon regulator	268934	G	-	T	123	97	-			-			Gly165Cys
630 and 630Δ*erm*														
CD630_2667	PTSG-BC	3080703	C	-	T	75	100	T	141	100	-			Val228Ile
IG	Intergenic region	2203033	A	-	T	105	100	T	174	99				
IG	Intergenic region	4007463			C	10	100	C	62	100				
630 and 630Δ*erm* and 630E														
CD630_11900	acyl-CoA N-acyltransferase	1391850	T	-	C	118	100	C	133	100	C	143	100	Phe133Leu
CD630_13880	pseudo	1607453	INS [1]	-	T	119	94	T	175	94	T	124	88	Thr16fs
Mistake in original sequence														
CD630_17670	*gapB*	2044514	C	G	G			G			G			
CD630_31561	pseudo	3686535	INS [1]	A	A			A			A			

The table shows the Single Nucleotide Polymorphism (SNP) changes in 630Δ*erm* and 630E compared to the reference 630 [12] and also the new annotation by Riedel *et al* (The column 'Gene' represents the gene (or intergenic region (IG)) in which the change occurs, the column 'position' indicates the exact nucleotide position of the change.). [22] It also contains SNP frequency (F) and genomic coverage (C) as well as the resultant amino acid change (AA). No change from the original 630 annotation [12] is represented by a dash (-).

Table 2. Strains and plasmids used in this study.

Name	Description	Source
Bacterial strains		
E. coli TOP 10	F– *mcrA* Δ(*mrr-hsdRMS-mcrBC*) Φ80*lacZ*ΔM15 Δ*lac*X74 *recA1 araD139* Δ (*ara leu*) 7697 *galU galK rpsL* (Str^R) *end*A1 nupG	Invitrogen
E. coli CA434	Conjugation donor	Williams et al. [36]
C. difficile 630	Wild-type	Brendan Wren
C. difficile 630Δ*erm*	Erythromycin sensitive strain of *C. difficile* 630	Hussain et al. [13]
C. difficile 630Δerm(ΔpyrE)	*C. difficile* 630Δ*erm* containing a deletion in the *pyrE* gene	Ng et al. [19]
C. difficile 630E	Erythromycin sensitive strain of *C. difficile* 630	Lyras et al. [8]
C. difficile 630Δ*erm* A+B-	*C. difficile* 630Δ*erm tcdB*-1511a::intron *ermB*	Kuehne et al. [9]
C. difficile 630E A+B-	*C. difficile* 630E	Lyras et al. [8]
C. difficile 630E A+B- CT	*C. difficile* 630E *tcdB*-1511a:: intron *ermB*	This study
C. difficile 630E_*topA*	*C. difficile* 630E	This study
C. difficile 630E_*flgB*	*C. difficile* 630E	This study
C. difficile 630E_CD2667	*C. difficile* 630E	This study
Plasmids		
pMTL007C-E2:*tcdB*-1511a	ClosTron plasmid containing retargeted region to *tcdB* at IS 1511 (antisense oriented) for *C. difficile* 630Δ*erm* or 630E	Kuehne et al. [9]

pMTL-SC7315λ2.3::*topA*	pMTL-SC7315λ2.3 containing 1,000 bp homology arms to change nucleotide 1480649 from T to C in 630E	This study, based on Cartman et al. [15]
pMTL-SC7315λ2.3::*flgB*	pMTL-SC7315λ2.3 containing 1,156 bp homology arms to reverse the inversion upstream of *flgB* in 630E	This study, based on Cartman et al. [15]
pMTL-SC7315λ2.3::CD2667	pMTL-SC7315λ2.3 containing 1,000 bp homology arms to change nucleotide 3079815 from C to A in 630E	This study, based on Cartman et al. [15]

Supporting Information

Figure S1. Southern and Western blot of 630E A+B- CT. A. Southern blot showing the single ClosTron insertion to create 630E A+B- CT (mutant 1, 2 and 3). The ClosTron plasmid pMTL007C-E2:*tcdB*-1511a was used as a positive control and the parental strain 630E as a negative control. The probe used binds to the intron insertion. B. Western blot using an anti-TcdA antibody to detect production of toxin A in the supernatant of 630, 630Δ*erm*, 630Δ*erm* A+B-, 630E, 630E A+B- and 630E A+B- CT after 96 h.

Table S1. Genomic and transcriptomic differences between 630, 630Δ*erm* and 630E.

SNPs, insertions (INS) and inversion (INV) are shown in this table as well as the corresponding RNAseq coverage. Changes between 630, 630Δ*erm* and 630E are represented compared to the published genome of 630, the new 630 genome by Riedel *et al*. [22] and also the newly published genome of 630Δ*erm* [23].

See attached excel file: S1_Table

Table S2. Colonisation of hamsters with *C. difficile* strains.

Colonisation of hamsters with 630E, 630E A+B- and 630E A+B- CT was confirmed by plating faecal and caecal samples on CDFA and by extraction genomic DNA and PCR of the toxin A and B genes.

Strain given	Colonisation	630 PCR	*tcdA*	*tcdB*	Succumbed to CDI
630E		Caecum	+	+	
630E	Colonised to Day 18	Faecal	+	+	
630E	Colonised to Day 15	Faecal	+	+	
630E		Caecum	+	+	CDI
630E		Caecum	+	+	CDI
630EA+B-		Caecum	+	-	CDI
630EA+B-	Not colonised	Faecal	-	-	
630EA+B-	Not colonised	Faecal	-	-	
630EA+B-	Not colonised	Faecal	-	-	
630EA+B-	Not colonised	Faecal	-	-	

630EA+B-		Caecum	+	-	
630EA+B-		Caecum	+	-	CDI
630EA+B-		Caecum	+	-	
630EA+B-	Colonised to Day 3	Faecal	+	-	
630EA+B-		Caecum	+	-	
630EA+B-		Caecum	+	-	
630E A+B- CT		Caecum	+	CT	CDI
630E A+B- CT		Caecum	+	CT	CDI
630E A+B- CT	Colonised to Day 15	Faecal	+	CT	
630E A+B- CT	Colonised to Day 18	Faecal	+	CT	
630E A+B- CT		Caecum	+	CT	
630E A+B- CT		Caecum	+	CT	

Table S3. Transcriptomic differences between 630, 630Δ*erm* and 630E.

Differentially expressed (DE) genes, comparing RNAseq data from 6 h to 14 h and 24 h in 630, 630Δ*erm* and 630E. The genes are classed into cell factor, cell growth, cell wall, fermentation, membrane transport, amino acid metabolism, carbon metabolism, cofactor metabolism, lipid metabolism, nucleic acid metabolism, mobile elements, motility, operons, regulation, anaerobic respiration, secretion, sporulation, stress, translation, unknown and virulence factors. Downregulated genes are coloured in green and upregulated genes in red.

See attached excel file: S3_Table

Table S4. Primers used in this study.

Primer name	**Sequence (5'-3')**	**Explanation or SNP target (where applicable)**
topAMC1	GATGCACAACAGGCAAGAAGAGTGC	To screen for chromosomal change
topAMC2b	CCCGATTGTAAAACAACTAGACCAATTATG	To screen for chromosomal change
flgBMC1b	CTATCAAATACAGATGGAAGTTGTGGTG	To screen for chromosomal change
flgBMC2c	CGAGCATATGATTCTAACGTAGATACATTGAATG	To screen for chromosomal change

CD2667MC1	GTCACCTTATGAGTGAAGTTTGTAATAAATGTGG	To screen for chromosomal change
CD2667MC2b	GCAAGAGCTGCTGCTGGAAGAC	To screen for chromosomal change
JRP3441 [8]	GTTACCAGGAATACAACCAGAC	To test for interrupted *tcdB*
JRP2839 [8]	CGGCCAGCCTCGCAGAGCAG	To test for interrupted *tcdB*
JRP3442 [8]	GCACTTGCTTGATCAAAGCTCC	*toxA* specific PCR, positive for all strains (630E, 630E A+B-, 630E A+B-CT)
JRP2342 [8]	CCGGAATTCGCTCTATTGGACTAGACCGTTG	*toxA* specific PCR, positive for all strains (630E, 630E A+B-, 630E A+B-CT)
Cdi-tcdB-F1 [9]	TGATAGTATAATGGCTGAAGCTAATGCAGATAATGG	To test for *tcdB* ClosTron insertion
Cdi-tcdB-R1 [9]	CTTGCATCGTCAAATGACC ATAAGCTAGCC	To test for *tcdB* ClosTron insertion
268934_F	TGTCAAGTGAATTAGAAAGAAACCA	268934
268934_R	AAGTGAGCCGTGTTTTGAAAA	268934
309208_F	GCCAGTTGCCAAAAAGAGTC	309208
309208_R	GGCATAGCATCATTTAGTGTTTC	309208
MCSNP11	CGGGAAAAACAGCTGCTTTTAGTATCCC	933139
MCSNP12	CCTCTTGCTTGTAAATCTCCTACCAATTC	933139
10000995_F	GATGAAGAAGTTGTTTGGCAAT	1000995
10000995_R	CCTACTTGGCTACACCTTTTACA	1000995
1391850_F	TCTGTCATTTGGAAAGGATGAA	1391850
1391850_R	TCTGTACTTGCTTTTGATATACTTGGA	1391850
Spo0A_F1	GGCATAGCTAAGGATGGAATTG	1413057
Spo0A_R1	GGAGTAGAGGAAAAGTTGACACAA	1413057
1480649_F	GCTTCAACAAGAAGGAGCAAA	1480649
1480649_R	TGCTGGTGGTTGTGTAAAATG	1480649
1607453_F	TTGAAGGTGTAAACTCAGTTGTAGG	1607453
1607453_R	TCCAAATAAAAGTCTATGAAAATGAA	1607453
1626977_F	TGGTGGTAGCAAAAACGAAA	1626977
1626977_R	TGCCATTGAATTTGTTGCAG	1626977
2044514_F	CATACTAAATGAGGGGTAAAATAAAGA	2044514
2044514_R	TTTTTCTGCCTTTTCTCTTTGTG	2044514
MCSNP1	GTTCTGTAATACCTTTTTCTTTAGCTATTTTAATTGC	2203033
MCSNP2	GTTACCGATATTATAGGCAAAACTGCCC	2203033
2209236_F	CCATTAGTGAGTGATGATTTACTTCC	2209236
2209236_R	GCAAGTTTTGCTATTTCTCTTTCTT	2209236
2320410_F	GTCACTGGTAGGAATTAATCTAACG	2320410
2320410_R	TGCTTTCACAAATGCTTTCG	2320410
MCSNP13	GAAAGATGAATTTCTATCCATCTTCATCAAATGTGG	2339506
MCSNP14	GGGGCTGTTGACCTTGGACCC	2339506

MCSNP3	CCTTTGATGTCTAGTTAATTTCTTCACTTATTTTAAGC	2937176
MCSNP4	GGAAAACCAGCAAAAGCTTGTATTATGATTCCC	2937176
3005866_F	AATATAATTCCCAACCTTCCAAA	3005866
3005866_R	TTTGTTTGAAGATTAGTGGTGATTG	3005866
MCSNP5	GTATATTTTTTCTCTAGCTTTATCTCCATCAGGG	3034953
MCSNP6	GGAAAGGATAAACCAGGTATAGTGGC	3034953
3079815_F	CCCGCTTTTACTTCATCTCC	3079815
3079815_R	GCATCAGAGATTTTGATTGCTTT	3079815
MCSNP7	CCTGCTACAAATTTTTTCTTTTCTGGC	3080703
MCSNP8	CTGCTTATCTTTATAAAAAGTTTTATAAAATTGAATTACCTC	3080703
MCSNP15	CTTCATATTGAGTGAAAGTCTGATTGAAGTTAGC	3422569
MCSNP16	CTCAACCGTGTGCCGTTTTCCCG	3422569
3526888_F	CTCTTTCCTGCATTCCCAAG	3526888
3526888_R	TTGTTGAGCAGATATAAAATCCCA	3526888
MCSNP17	CAATCTATTCAAAGATAAACTATAGTACTTCTTCTAC	3528736
MCSNP18	CCTACTCCTTTAGGTGTGAGATGG	3528736
3591103_F	GGCACTAGCTGCTCCTAATAAA	3591103
3591103_R	CCATATACCCCTATCCCTCCTT	3591103
3686535_F	TCTTCCAAGCTCTTACCTGTTTG	3686535
3686535_R	GCTCTGTCCAGTTAATTG	3686535
3797112_F	TGCTCCTGTAAATGCACCTG	3797112
3797112_R	CTGTAAAATACAAGTCACTCATTCCAA	3797112
MCSNP19	CCGTTCCAGACTGTTCAATGCTCC	3951559
MCSNP20	CCTAAGTAGTAGTTACTGGCAACAGCAC	3951559
MCSNP9	GCACCCTTAATAACTTGACCAGTTAAAAAGG	4007463
MCSNP10	CGCCCGAAGCCGATTATCTAACC	4007463
4166495_F	GCATCAAGTAAGTATTTATGCTCTTCA	4166495
4166495_R	TGAACTTGGATAATTACAAGCCATT	4166495